# US 2013/0252967 A1 · 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252967 A1
- Document ID: US20130252967A1
- Status: Published application
- Kind: A1
- Application number: 13/702,963
- Filed: 2011-06-10
- Published: 2013-09-26
- Earliest claimed: 2010-06-10
- Assignees: Afraxis, Inc.
- Inventors: David Campbell; Sergio G. Duron; Benedikt Vollrath; Warren Wade
- Web page: https://patentgrep.com/patent/US20130252967A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders.

## Claims

### Claim 1

A compound having the structure of Formula I or a pharmaceutically acceptable salt or N-oxide thereof:
wherein:
R1 and R2 are each independently H or substituted or unsubstituted alkyl; or R1 and R2 together with the carbon to which they are attached form a C3-C6 cycloalkyl ring;
p is 1, 2 or 3;
ring A is aryl or heteroaryl;
R3 is S(═O)R9 or —S(═O)2R9;
each R4 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCF2H, —OCH2F, —CF3, —SR8, —S(═O)R9, —S(═O)2R9, —NR10S(═O)2R9, —S(═O)2N(R10)2, —OR10, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl;
R8 is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
R9 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
each R10 is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or two R10 together with the atoms to which they are attached form a heterocycle;
s is 0-4;
ring B is aryl or heteroaryl;
each R5 is independently halogen, —CN, —NO2, —OH, —SR8, —S(═O)R9, —S(═O)2R9, NR10S(═O)2R9, —S(═O)2N(R10)2, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, —OR10, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl;
r is 0-8; and
R7 is H, halogen, —CN, substituted or unsubstituted alkyl, —C(═O)N(R10)2, —CO2R10, —OR10, —N(R10)2, acyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

### Claim 2

A compound having the structure of Formula IA or a pharmaceutically acceptable salt or N-oxide thereof:
wherein:
R1 and R2 are each independently H or substituted or unsubstituted alkyl; or R1 and R2 together with the carbon to which they are attached form a C3-C6 cycloalkyl ring;
p is 1, 2 or 3;
ring A is aryl or heteroaryl;
R3 is —S(═O)R9 or —S(═O)2R9;
each R4 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCF2H, —OCH2F, —CF3, —SR8, —S(═O)R9, —S(═O)2R9, —NR10S(═O)2R9, —S(═O)2N(R10)2, —OR10, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl;
R8 is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
R9 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
each R10 is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or two R10 together with the atoms to which they are attached form a heterocycle;
s is 0-4;
ring B is aryl or heteroaryl;
each R5 is independently halogen, —CN, —NO2, —OH, —SR8, —S(═O)R9, —S(═O)2R9, NR10S(═O)2R9, —S(═O)2N(R10)2, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, —OR10, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl;
r is 0-8; and
R7 is H, halogen, —CN, substituted or unsubstituted alkyl, —OR10, —C(═O)N(R10)2, —CO2R10, —N(R10)2, acyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
provided that the compound of Formula IA is not 2-(4-(4-methylpiperazin-1-yl)phenylamino)-8-(2-(methylsulfonyl)benzyl)pyrido[2,3-d]pyrimidin-7 (8H)-one, 8-(2-fluoro-6-(methylsulfinyl)benzyl)-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one, or 8-(2-fluoro-6-(methylsulfinyl)benzyl)-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrido[2,3-d]pyrimidin-7 (8H)-one.

### Claim 3 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R3 is (R)—S(═O)R9 or (S)—S(═O)R9.

### Claim 4 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein ring A is a 5-10-membered heteroaryl ring comprising 1-4 nitrogen atoms, 1-2 oxygen atoms, 1-2 sulfur atoms, or any combination thereof.

### Claim 5 (depends on 4)

The compound of claim 4 or a pharmaceutically acceptable salt or N-oxide thereof, wherein ring A is selected from pyrrole, furan, thiophene, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, 1,2,3-triazole, 1,3,4-triazole, 1-oxa-2,3-diazole, 1-oxa-2,4-diazole, 1-oxa-2,5-diazole, 1-oxa-3,4-diazole, 1-thia-2,3-diazole, 1-thia-2,4-diazole, 1-thia-2,5-diazole, 1-thia-3,4-diazole, tetrazole, pyridine, pyridazine, pyrimidine, and pyrazine.

### Claim 6 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein ring A is an aryl ring.

### Claim 7 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein ring B is a heteroaryl ring selected from pyrrole, furan, thiophene, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, 1,2,3-triazole, 1,3,4-triazole, 1-oxa-2,3-diazole, 1-oxa-2,4-diazole, 1-oxa-2,5-diazole, 1-oxa-3,4-diazole, 1-thia-2,3-diazole, 1-thia-2,4-diazole, 1-thia-2,5-diazole, 1-thia-3,4-diazole, tetrazole, pyridine, pyridazine, pyrimidine, and pyrazine.

### Claim 8 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein ring B is an aryl ring.

### Claim 9 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein each R5 is independently halogen, —CN, —OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, —NR10S(═O)2R9, —S(═O)2N(R10)2, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, —OR10, or substituted or unsubstituted heterocycloalkyl.

### Claim 10 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein each R5 is independently —NR10S(═O)2R9, —S(═O)2N(R10)2, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, —OR10, or substituted or unsubstituted heterocycloalkyl.

### Claim 11 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein each R5 is independently —N(R10)2, or substituted or unsubstituted heterocycloalkyl.

### Claim 12 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein each R5 is independently a substituted or unsubstituted piperazine, substituted or unsubstituted piperidine, substituted or unsubstituted pyrrolidine, or substituted or unsubstituted morpholine.

### Claim 13 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein one R5 is —OR10.

### Claim 14 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein each R4 is independently halogen, —CN, —OH, —OCF3, —OCF3, —OCF2H, —CF3, —SR8, —S(═O)R9, —S(═O)2R9, or substituted or unsubstituted alkyl, or substituted or unsubstituted alkoxy.

### Claim 15 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein s is 0.

### Claim 16 (depends on 1)

The compound of claim 1, having a structure of Formula II or a pharmaceutically acceptable salt or N-oxide thereof:

### Claim 17 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R7 is H.

### Claim 18 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R7 is —CN.

### Claim 19 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R7 is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, or substituted or unsubstituted cyclohexyl.

### Claim 20 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R7 is substituted or unsubstituted morpholine, substituted or unsubstituted piperazine, or substituted or unsubstituted piperidine.

### Claim 21 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R7 is substituted or unsubstituted acyl.

### Claim 22 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R7 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 23 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R7 is —OR10.

### Claim 24 (depends on 22)

The compound of claim 22 or a pharmaceutically acceptable salt or N-oxide thereof wherein R7 is
wherein:
ring T is aryl, or heteroaryl;
R3a is H or R4a;
each R4a is independently halogen, —CN, —NO2, —OH, —OCF3, —OCF2H, —OCH2F, —CF3, —SR8, —NR10S(═O)2R9, —S(═O)2N(R10)2, —C(═O)R9, —OC(═O)R9, —CO2R10, —N(R10)2, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10C(═O)OR10, —NR10C(═O)N(R10)2, —OR10, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl;
R8 is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
R9 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl;
each R10 is independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, or two R10 together with the atoms to which they are attached form a heterocycle; and
s is 0-4.

### Claim 25 (depends on 24)

The compound of claim 24 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R7 is aryl and R4a is halogen.

### Claim 26 (depends on 24)

The compound of claim 24 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R7 is a heteroaryl and R4a is H, alkyl, cycloalkyl, heterocycloalkyl or heteroaryl.

### Claim 27 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein p is 1; and R1 and R2 are H.

### Claim 28 (depends on 1)

The compound of claim 1, having a structure of Formula IIA or IIB or a pharmaceutically acceptable salt or N-oxide thereof:

### Claim 29 (depends on 1)

The compound of claim 1, having a structure of Formula III or a pharmaceutically acceptable salt or N-oxide thereof:

### Claim 30 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein ring A is a phenyl ring.

### Claim 31 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein ring A is a phenyl ring substituted with halogen.

### Claim 32 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein ring A is a phenyl ring substituted with a substituted or unsubstituted alkyl or trifluoromethyl.

### Claim 33

A compound selected from:
and pharmaceutically acceptable salts and N-oxides thereof.

### Claim 34 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof and a pharmaceutically acceptable carrier.

### Claim 35 (depends on 1)

A method of inhibiting or partially inhibiting the activity of a p21-activated kinase comprising contacting the kinase with a compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof.

### Claim 36 (depends on 35)

The method of claim 35 wherein the p21-activated kinase is contacted with the compound in vivo.

### Claim 37 (depends on 35)

The method of claim 35, wherein the p21-activated kinase is contacted with the compound in vitro.

### Claim 38 (depends on 35)

The method of claim 35, wherein the p21-activated kinase is PAK1, PAK2, PAK3, PAK4, PAK5, or PAK6.

### Claim 39 (depends on 35)

The method of claim 35, wherein the p21-activated kinase is a Group I p21-activated kinase.

### Claim 40 (depends on 35)

The method of claim 35, wherein said contacting causes substantially complete inhibition of one of more Group I p21-activated kinases.

### Claim 41 (depends on 35)

The method of claim 35, wherein said contacting causes partial inhibition of one of more Group I p21-activated kinases.

### Claim 42 (depends on 35)

The method of claim 35, wherein said contacting modulates dendritic spine morphology or synaptic function.

### Claim 43 (depends on 35)

The method of claim 35, wherein said contacting modulates dendritic spine density.

### Claim 44 (depends on 35)

The method of claim 35, wherein said contacting modulates dendritic spine length.

### Claim 45 (depends on 35)

The method of claim 35, wherein said contacting modulates dendritic spine neck diameter.

### Claim 46 (depends on 35)

The method of claim 35, wherein said contacting modulates dendritic spine head diameter.

### Claim 47 (depends on 1)

A method of treating a CNS disorder in an individual comprising administering to an individual in need thereof a therapeutically effective amount of a compound of claim 1.

### Claim 48 (depends on 47)

The method of claim 47, wherein the CNS disorder is a neuropsychiatric, neurodegenerative or neurodevelopmental disorder.

### Claim 49 (depends on 47)

The method of claim 47, wherein the CNS disorder is schizophrenia, Alzheimer's disease, Mild cognitive impairment, autism, an autism spectrum disorder, neurofibromatosis, bipolar disorder, or depression.

### Claim 50 (depends on 49)

The method of claim 49 wherein the autism spectrum disorder is selected from Fragile X, Retts Aspergers, and Angelman syndrome.

### Claim 51 (depends on 47)

The method of claim 47, wherein said administering normalizes or partially normalizes aberrant synaptic plasticity associated with a CNS disorder.

### Claim 52 (depends on 47)

The method of claim 47, wherein said administering normalizes or partially normalizes aberrant long term depression (LTD) associated with a CNS disorder.

### Claim 53 (depends on 47)

The method of claim 47, wherein said administering normalizes or partially normalizes aberrant long term potentiation (LTP) associated with a CNS disorder.

### Claim 54 (depends on 1)

A method of treating a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt or N-oxide thereof.
